2020
DOI: 10.1111/bcpt.13379
|View full text |Cite
|
Sign up to set email alerts
|

Use of proton pump inhibitors and mortality among Icelandic patients with prostate cancer

Abstract: This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2
2

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 38 publications
(42 reference statements)
0
1
0
Order By: Relevance
“…The same was perceived when PPIs were synergistically administered with raloxifene to T47D cells ( 103 ), another breast cancer cell line, suppressing cell growth compared to the raloxifene alone. PPI administration was also evaluated in Prostate cancer patients, yet no significant results indicated their effectiveness as a cancer drug ( 104 ). HKA (coded by ATP4A, ATP4B and ATP12A) is expressed in pancreatic ducts and is responsible for regulating the secretion of pancreatic fluid but is also expressed in pancreatic cancer cells.…”
Section: Hkamentioning
confidence: 99%
“…The same was perceived when PPIs were synergistically administered with raloxifene to T47D cells ( 103 ), another breast cancer cell line, suppressing cell growth compared to the raloxifene alone. PPI administration was also evaluated in Prostate cancer patients, yet no significant results indicated their effectiveness as a cancer drug ( 104 ). HKA (coded by ATP4A, ATP4B and ATP12A) is expressed in pancreatic ducts and is responsible for regulating the secretion of pancreatic fluid but is also expressed in pancreatic cancer cells.…”
Section: Hkamentioning
confidence: 99%